Cullinan oncology to present data demonstrating progress across its broad immunotherapy-pipeline at sitc 2023

Five abstracts accepted for poster presentation at the society for immunotherapy of cancer 2023 annual meeting preliminary clinical biomarker data for anti-mica/b antibody, cln-619, supports proposed mechanism of action and demonstrates that the observed monotherapy clinical activity was seen in patients with tumors not typically responsive to checkpoint inhibitor therapy   data highlight progress of cullinan's diverse pipeline including cln-619, an anti-mica/b antibody; cln-418, a b7h4x4-1bb-bispecific immune activator; cln-978, a cd19xcd3 bispecific t cell engager; and cln-617, a fusion protein harnessing il-2 and il-12 cytokines cambridge, mass., nov. 03, 2023 (globe newswire) -- cullinan oncology, inc. (nasdaq: cgem) (“cullinan”), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that it will present data across four distinct immuno-oncology programs in five poster presentations at the society for immunotherapy of cancer (sitc) 2023 annual meeting taking place november 1-5 in san diego.
CGEM Ratings Summary
CGEM Quant Ranking